Protocol Ledger

NCT05775848 · Phase III · ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Interventional Phase III clinical trial protocol NCT05775848 sponsored by ML Bio Solutions in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-05-31 Enrollment: 112 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05775848
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)112 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05775848
Protocol FieldVerified Registry Value
NCT IdentifierNCT05775848
Consolidated Lead SponsorML Bio Solutions
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment112 participants (ACTUAL)
Registered Start Date2023-05-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI